Table 1.
Baseline Characteristics Infusion Arms.
| Clinical Characteristics- No. (%) | EDTA Chelation (N= 839) |
Placebo (N= 869) |
|---|---|---|
| Age-years | 65 (59, 72) | 66 (59, 72) |
| Female | 152 (18) | 147 (17) |
| Caucasian | 790 (94) | 815 (94) |
| Hispanic | 22 (3) | 29 (3) |
| Black or African American | 29 (3) | 31 (4) |
| Asian | 10 (1) | 18 (2) |
| American Indian/ Alaska Native | 11 (1) | 6 (1) |
| Native Hawaiian or Other Pacific Islander | 3 (0.4) | 3 (0.3) |
| BMI (kg/m2) | 30 (27, 34) | 30 (27, 34) |
| Blood Pressure (mmHg) | ||
| Systolic | 130 (120, 140) | 130 (120, 140) |
| Diastolic | 76 (70, 80) | 76 (70, 80) |
| History- No. (%) | ||
| Hypercholesterolemia | 676 (82) | 694 (81) |
| Hypertension | 568 (68) | 601 (69) |
| Former cigarette smoker | 467 (56) | 488 (56) |
| Angina pectoris | 461 (55) | 465 (54) |
| Anterior MI | 337 (40) | 337 (39) |
| Diabetes | 265 (32) | 273 (31) |
| Congestive heart failure | 154 (18) | 153 (18) |
| Peripheral vascular disease | 126 (15) | 142 (16) |
| Valvular heart disease | 92 (11) | 83 (10) |
| Atrial fibrillation | 85 (10) | 110 (13) |
| Stroke | 57 (7) | 54 (6) |
| Time from qualifying MI to randomization-years | 4.3 (1.8, 9.1) | 4.8 (1.5, 9.5) |
| Current NYHA heart failure class- No. (%) | ||
| No heart failure or Class I | 764 (91) | 795 (91) |
| Class II | 63 (8) | 59 (7) |
| Class III | 12 (1) | 15 (2) |
| Class IV | 0 | 0 |
| Coronary revascularizations- No. (%) | ||
| Either CABG or PCI | 694 (83) | 720 (83) |
| PCI | 491 (59) | 516 (59) |
| CABG | 384 (46) | 390 (45) |
| Concomitant Medications- No. (%) | ||
| Aspirin, warfarin or clopidogrel | 768 (92) | 784 (90) |
| Aspirin* | 717 (85) | 710 (82) |
| Beta-blocker | 611 (73) | 615 (71) |
| Statin | 615 (73) | 633 (73) |
| ACEI or ARB | 525 (63) | 559 (64) |
| Clopidogrel | 212 (26) | 213 (25) |
| Warfarin | 73 (9) | 75 (9) |
| Diabetes medication | ||
| Oral hypoglycemic | 191 (24) | 189 (23) |
| Insulin | 73 (9) | 87 (10) |
| Multivitamin | 356 (44) | 359 (43) |
| Other vitamins/minerals | 428 (52) | 424 (50) |
| Herbal products | 281 (34) | 279 (34) |
| Laboratory Examinations (mg/dL) | ||
| Total cholesterol | 164 (139, 192) | 166 (143, 198) |
| Triglycerides | 135 (94, 199) | 147 (99, 208) |
| Glucose | 103 (92, 121) | 102 (92, 121) |
| LDL | 87 (66, 112) | 90 (68, 117) |
| HDL | 43 (36, 52) | 43 (36, 50) |
| Creatinine* | 1.1 (0.9, 1.2) | 1.1 (0.9, 1.2) |
*
P<0.05.
There were no other statistically significant differences between groups. Continuous data are reported as median (IQR).
Abbreviations used: ACEI= angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; HDL = high-density lipoprotein; LDL = low-density lipoprotein.